MA28631B1 - Antagonistes des recepteurs muscariniques de l'acetylcholine - Google Patents

Antagonistes des recepteurs muscariniques de l'acetylcholine

Info

Publication number
MA28631B1
MA28631B1 MA29426A MA29426A MA28631B1 MA 28631 B1 MA28631 B1 MA 28631B1 MA 29426 A MA29426 A MA 29426A MA 29426 A MA29426 A MA 29426A MA 28631 B1 MA28631 B1 MA 28631B1
Authority
MA
Morocco
Prior art keywords
antagonists
acetylcholine receptors
muscarinic acetylcholine
muscarinic
receptors
Prior art date
Application number
MA29426A
Other languages
English (en)
French (fr)
Inventor
Dramane I Laine
Michael R Palovich
Brent W Mccleland
Christopher E Neipp
Sonia M Thomas
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35242158&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA28631(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA28631B1 publication Critical patent/MA28631B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/452—Piperidinium derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
MA29426A 2004-04-27 2006-10-31 Antagonistes des recepteurs muscariniques de l'acetylcholine MA28631B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56562304P 2004-04-27 2004-04-27

Publications (1)

Publication Number Publication Date
MA28631B1 true MA28631B1 (fr) 2007-06-01

Family

ID=35242158

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29426A MA28631B1 (fr) 2004-04-27 2006-10-31 Antagonistes des recepteurs muscariniques de l'acetylcholine

Country Status (38)

Country Link
US (9) US7498440B2 (en:Method)
EP (3) EP1740177B1 (en:Method)
JP (2) JP5014121B2 (en:Method)
KR (2) KR101152032B1 (en:Method)
CN (2) CN1976701A (en:Method)
AP (1) AP2213A (en:Method)
AR (1) AR050902A1 (en:Method)
AU (1) AU2005237576B2 (en:Method)
BE (1) BE2014C063I2 (en:Method)
BR (1) BRPI0510170B8 (en:Method)
CA (2) CA2564742C (en:Method)
CY (3) CY1113196T1 (en:Method)
DK (2) DK2570128T3 (en:Method)
EA (2) EA021994B1 (en:Method)
EC (1) ECSP066940A (en:Method)
ES (2) ES2600405T3 (en:Method)
FR (1) FR14C0075I2 (en:Method)
HR (2) HRP20120832T1 (en:Method)
HU (2) HUE031304T2 (en:Method)
IL (1) IL178152A (en:Method)
LT (1) LT2570128T (en:Method)
LU (1) LU92565I2 (en:Method)
MA (1) MA28631B1 (en:Method)
MX (1) MXPA06012405A (en:Method)
MY (1) MY144753A (en:Method)
NL (1) NL300694I1 (en:Method)
NO (3) NO338959B1 (en:Method)
NZ (1) NZ549997A (en:Method)
PE (1) PE20060259A1 (en:Method)
PL (2) PL1740177T3 (en:Method)
PT (2) PT1740177E (en:Method)
SG (1) SG186597A1 (en:Method)
SI (2) SI1740177T1 (en:Method)
TW (1) TWI363759B (en:Method)
UA (1) UA95768C2 (en:Method)
UY (1) UY28871A1 (en:Method)
WO (1) WO2005104745A2 (en:Method)
ZA (1) ZA200608565B (en:Method)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200519108A (en) * 2003-07-17 2005-06-16 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
EA200600787A1 (ru) * 2003-10-17 2006-08-25 Глэксо Груп Лимитед Антагонисты мускариновых ацетилхолиновых рецепторов
PE20050489A1 (es) * 2003-11-04 2005-09-02 Glaxo Group Ltd Antagonistas de receptores de acetilcolina muscarinicos
US20090253908A1 (en) * 2004-03-11 2009-10-08 Glaxo Group Limited Novel m3 muscarinic acetylchoine receptor antagonists
WO2005095407A1 (en) * 2004-03-17 2005-10-13 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
US20070185148A1 (en) * 2004-03-17 2007-08-09 Glaxo Group Limited M3 muscarinic acetylchoine receptor antagonists
JP2007531792A (ja) * 2004-04-05 2007-11-08 サマリタン，ファーマスーティカルス，インク． 抗ｈｉｖキヌクリジン化合物
PE20060259A1 (es) 2004-04-27 2006-03-25 Glaxo Group Ltd Compuestos de quinuclidina como antagonistas del receptor de acetilcolina muscarinico
JP2007537261A (ja) * 2004-05-13 2007-12-20 グラクソ　グループ　リミテッド ムスカリン性アセチルコリン受容体アンタゴニスト
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
US7932247B2 (en) * 2004-11-15 2011-04-26 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
EP1937267A4 (en) * 2005-08-02 2009-08-26 Glaxo Group Ltd M3-MUSCARIN ACETYLCHOLIN RECEPTOR ANTAGONISTS
JP2009504768A (ja) * 2005-08-18 2009-02-05 グラクソ グループ リミテッド ムスカリン性アセチルコリン受容体アンタゴニスト
TW200811111A (en) 2006-04-20 2008-03-01 Glaxo Group Ltd Novel compounds
GB0611587D0 (en) 2006-06-12 2006-07-19 Glaxo Group Ltd Novel compounds
PT2046787E (pt) 2006-08-01 2011-06-15 Glaxo Group Ltd Compostos de pirazolo[3,4-b]piridina e sua utilização como inibidores de pde4
PE20081889A1 (es) 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
CL2009000249A1 (es) 2008-02-06 2009-09-11 Glaxo Group Ltd Compuestos derivados de pirazolo[3,4-b] piridin-butanodiamida; composicion farmaceutica; y su uso en el tratamiento del asma, enfermedad pulmonar obstructiva cronica, rinitis, dermatitis atopica, psoriasis.
TW200946526A (en) 2008-02-06 2009-11-16 Glaxo Group Ltd Dual pharmacophores-PDE4-muscarinic antagonistics
TW201000476A (en) 2008-02-06 2010-01-01 Glaxo Group Ltd Dual pharmacophores-PDE4-muscarinic antagonistics
US8765743B2 (en) 2008-06-05 2014-07-01 Glaxosmithkline Intellectual Property Development Limited Compounds
JP5502858B2 (ja) 2008-06-05 2014-05-28 グラクソ グループ リミテッド Ｐｉ３キナーゼの阻害剤として有用な４−カルボキサミドインダゾール誘導体
WO2010094643A1 (en) 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
SI3578169T1 (sl) 2009-02-26 2024-09-30 Glaxo Group Limited Farmacevtske formulacije, ki obsegajo 4-((1R)-2-((6-(2-((2,6-dikloro- benzil)oksi)etoksi)heksil)amino)-1-hidroksietil)-2-(hidroksimetil)fenol
JP5656880B2 (ja) 2009-03-09 2015-01-21 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ Ｐｉ３キナーゼの阻害剤としての４−オキサジアゾール−２−イル−インダゾール
JP2012520257A (ja) 2009-03-10 2012-09-06 グラクソ グループ リミテッド Ｉｋｋ２阻害剤としてのインドール誘導体
EP2408769A1 (en) 2009-03-17 2012-01-25 Glaxo Group Limited Pyrimidine derivatives used as itk inhibitors
AR076435A1 (es) 2009-04-30 2011-06-08 Glaxo Group Ltd Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos
WO2011029896A1 (en) 2009-09-11 2011-03-17 Glaxo Group Limited Methods of preparation of muscarinic acetylcholine receptor antagonists
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
EP2507226A1 (en) 2009-12-03 2012-10-10 Glaxo Group Limited Novel compounds
WO2011067365A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Benzpyrazole derivatives as inhibitors of p13 kinases
WO2011067366A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Indazole derivatives as pi 3 - kinase inhibitors
CN102947309B (zh) * 2010-01-28 2016-02-10 西伦制药公司 7-氮*双环[2.2.1]庚烷衍生物、其制备方法、及其制可药用途
WO2011110575A1 (en) 2010-03-11 2011-09-15 Glaxo Group Limited Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
MX2012014541A (es) * 2010-06-22 2013-01-29 Chiesi Farma Spa Formulacion en polvo seca que comprende farmaco antimuscarinico.
WO2012032067A1 (en) 2010-09-08 2012-03-15 Glaxo Group Limited Polymorphs and salts of n- [5- [4- (5- { [(2r,6s) -2, 6 - dimethyl - 4 -morpholinyl] methyl} - 1, 3 - oxazol - 2 - yl) - 1h- inda zol-6-yl] -2- (methyloxy) - 3 - pyridinyl] methanesulfonamide
WO2012035055A1 (en) 2010-09-17 2012-03-22 Glaxo Group Limited Novel compounds
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
KR20140041700A (ko) 2011-06-08 2014-04-04 글락소 그룹 리미티드 우메클리디늄을 포함하는 건조 분말 흡입기 조성물
KR20140041699A (ko) 2011-06-08 2014-04-04 글락소 그룹 리미티드 우메클리디늄 및 코르티코스테로이드를 포함하는 조합물
AU2013246926B2 (en) 2012-04-13 2016-07-21 Glaxosmithkline Intellectual Property Development Limited Aggregate particles
RU2502743C1 (ru) * 2012-08-03 2013-12-27 Федеральное государственное бюджетное учреждение "Российский кардиологический научно-производственный комплекс" Министерства здравоохранения и социального развития РФ (ФГБУ "РКНПК" Минздравсоцразвития России) Синтетический антиген, обладающий способностью связывать аутоантитела к мускариновому м2-рецептору
KR20150043465A (ko) * 2012-08-15 2015-04-22 글락소 그룹 리미티드 화학 공정
GB201222679D0 (en) 2012-12-17 2013-01-30 Glaxo Group Ltd Pharmaceutical combination products
KR101823451B1 (ko) * 2013-07-13 2018-01-30 베이징 에프에스웰컴 테크놀로지 디벨롭먼트 컴퍼니 리미티드 퀴논계 화합물, 이의 광학 이성질체 및 이의 제조 방법과 의약 용도
MX2016001465A (es) 2013-07-30 2016-06-02 Glaxosmithkline Ip Dev Ltd Composiciones topicas para el tratamiento de sudoracion excesiva y metodos para utilizar las mismas.
CN105611929A (zh) 2013-10-17 2016-05-25 葛兰素史克知识产权开发有限公司 用于治疗呼吸系统疾病的pi3k抑制剂
CN105658218A (zh) 2013-10-17 2016-06-08 葛兰素史克知识产权开发有限公司 用于治疗呼吸疾病的pi3k抑制剂
TW201625247A (zh) 2014-05-12 2016-07-16 葛蘭素史密斯克藍智慧財產權有限公司 用於治療傳染性疾病之醫藥組合物
EP3650019B8 (en) 2014-05-28 2023-10-11 GlaxoSmithKline Intellectual Property Development Limited Fluticasone furoate in the treatment of copd
JP6615212B2 (ja) * 2014-11-03 2019-12-04 オロン ソシエタ ペル アチオニ １−（２−ハロゲン−エチル）−４−ピぺリジンカルボン酸エチルエステルの製法
KR101613245B1 (ko) 2015-04-27 2016-04-18 주식회사 대웅제약 신규의 4-메톡시 피롤 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
CN105461710A (zh) * 2015-10-23 2016-04-06 安徽德信佳生物医药有限公司 一种芜地溴铵的制备方法
JP7015549B2 (ja) * 2016-01-08 2022-02-03 セロン ファーマシューティカルズ， インク ７－アゾニアビシクロ［２．２．１］ヘプタン誘導体の乾燥粉末吸入器組成物
GB201602527D0 (en) 2016-02-12 2016-03-30 Glaxosmithkline Ip Dev Ltd Chemical compounds
CN107200734B (zh) * 2016-03-18 2019-12-24 益方生物科技（上海）有限公司 奎宁环衍生物及其制备方法和用途
EP3248970A1 (en) 2016-05-27 2017-11-29 Zentiva K.S. Forms of umeclidinium bromide
EP3497100A1 (en) 2016-08-08 2019-06-19 GlaxoSmithKline Intellectual Property Development Limited Chemical compounds
PT109740B (pt) * 2016-11-14 2020-07-30 Hovione Farmaciencia Sa Processo para a preparação de brometo de umeclidínio
WO2018163212A1 (en) * 2017-03-08 2018-09-13 Gbr Laboratories Pvt. Ltd A process for the preparation of umeclidinium bromide and intermediates thereof
GB201706102D0 (en) 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
IT201700058796A1 (it) * 2017-05-30 2018-11-30 Olon Spa Procedimento per la preparazione di un nuovo intermedio di sintesi dell’umeclidinio.
GB201712081D0 (en) 2017-07-27 2017-09-13 Glaxosmithkline Ip Dev Ltd Chemical compounds
JP7432506B2 (ja) 2017-10-30 2024-02-16 武田薬品工業株式会社 脂質エンベロープウイルスを不活化するための環境適合性の界面活性剤
CN108558860B (zh) * 2018-06-04 2020-12-25 成都伊诺达博医药科技有限公司 一种合成芜地溴铵的方法
US11484531B2 (en) 2018-08-30 2022-11-01 Theravance Biopharma R&D Ip, Llc Methods for treating chronic obstructive pulmonary disease
PT115583B (pt) 2019-06-17 2022-05-02 Hovione Farm S A Processo contínuo para a preparação de medicamentos anticolinérgicos
CN113387923A (zh) * 2020-03-13 2021-09-14 诺华股份有限公司 硫辛酸胆碱酯盐的药物组合物及使用其的治疗方法
CA3173172A1 (en) 2020-03-26 2021-09-30 Christopher D. Kane Cathepsin inhibitors for preventing or treating viral infections
CN111484445B (zh) * 2020-04-21 2021-05-18 广东莱佛士制药技术有限公司 分离纯化高纯度乌美溴铵的中间体的方法
US12358908B2 (en) 2020-04-26 2025-07-15 Beijing Showby Pharmaceutical Co., Ltd. Crystals, preparation method and application of a muscarinic receptor antagonist
IL301285A (en) 2020-09-10 2023-05-01 Precirix N V Antibody fragment against fap
CN112479983B (zh) * 2020-11-25 2022-07-12 江苏豪森药业集团有限公司 乌美溴铵中间体及其制备方法
PT117440B (pt) 2021-09-03 2024-04-26 Hovione Farm S A Processo para a preparação de aminas cíclicas cloroaquilo substituídas
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
AU2023264245A1 (en) 2022-05-02 2024-12-19 Precirix N.V. Pre-targeting
WO2024251812A1 (en) 2023-06-07 2024-12-12 Pharmazell Gmbh A process for the preparation of umeclidinium bromide intermediate

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2800478A (en) 1955-07-01 1957-07-23 Smith Kline French Lab 3-substituted-8-alkylnortropanes and the acid and quaternary ammonium salts thereof
US2800481A (en) 1955-07-01 1957-07-23 Smith Kline French Lab Tertiary alcohol derivatives of 8-alkylnortropanes and the acid and quaternary ammonium salts thereof
AT298118B (de) 1967-06-08 1972-04-25 Siemens Ag Verfahren zur Umsetzung von Spannungen in digitale Werte und Vorrichtung zur Durchführung des Verfahrens
GB1242211A (en) 1967-08-08 1971-08-11 Fisons Pharmaceuticals Ltd Pharmaceutical composition
GB1230087A (en:Method) 1967-08-17 1971-04-28
GB1381872A (en) 1971-06-22 1975-01-29 Fisons Ltd Pharmaceutical compositions for inhalation
CY1308A (en) 1979-12-06 1985-12-06 Glaxo Group Ltd Device for dispensing medicaments
DE3274065D1 (de) 1981-07-08 1986-12-11 Draco Ab Powder inhalator
FR2550452B1 (fr) 1982-10-08 1992-05-22 Glaxo Group Ltd Dispositif pour administrer des medicaments a des patients
GB2169265B (en) 1982-10-08 1987-08-12 Glaxo Group Ltd Pack for medicament
BR8603576A (pt) 1985-07-30 1987-03-04 Glaxo Group Ltd Dispositivos para administrar medicamentos a pacientes
IT1204826B (it) 1986-03-04 1989-03-10 Chiesi Farma Spa Composizioni farmaceutiche per inalazione
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
US5780466A (en) 1995-01-30 1998-07-14 Sanofi Substituted heterocyclic compounds method of preparing them and pharmaceutical compositions in which they are present
EP0944626A4 (en) 1996-12-02 2002-09-04 Univ Georgetown TROPANDERIVATIVES AND METHOD FOR YOUR SYNTHESIS
US6248752B1 (en) 1998-02-27 2001-06-19 Charles Duane Smith Azabicyclooctane compositions and methods for enhancing chemotherapy
US6262066B1 (en) 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
PL363807A1 (en) * 2000-12-28 2004-11-29 Almirall Prodesfarma Ag Novel quinuclidine derivatives and medicinal compositions containing the same
CZ2004501A3 (cs) 2001-10-17 2004-09-15 Ucb, S.A. Chinuklidinové deriváty, způsoby jejich přípravy a jejich použití jako M2 a/nebo M3 inhibitoru muskarinového receptoru
CA2466344A1 (en) * 2001-11-09 2003-05-22 Pharmacia & Upjohn Company Azabicyclic-phenyl-fused-heterocyclic compounds and their use as alpha7 nachr ligands
JP4505227B2 (ja) * 2001-12-20 2010-07-21 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ １−アルキル−１−アゾニアビシクロ［２．２．２］オクタンカルバメート誘導体およびムスカリンレセプターアンタゴニストとしてのそれらの使用
US6696462B2 (en) * 2002-01-31 2004-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Anticholinergics, processes for the preparation thereof, and pharmaceutical compositions
ES2206021B1 (es) 2002-04-16 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirrolidinio.
ES2204295B1 (es) * 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
UY27927A1 (es) 2002-08-06 2003-12-31 Glaxo Group Ltd Antagonistas del receptor muscarínico m3 de acetilcolina
US7232841B2 (en) 2003-04-07 2007-06-19 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
TW200523261A (en) 2003-07-17 2005-07-16 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
PE20050711A1 (es) 2003-07-17 2005-09-10 Glaxo Group Ltd Compuestos 8-azoniabiciclo[3.2.1] octanos como antagonistas de los receptores muscarinicos de la acetilcolina
TW200519108A (en) 2003-07-17 2005-06-16 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
UA89734C2 (en) 2003-10-14 2010-02-25 Глаксо Груп Лимитед ANTAGONISTS of muscarinic acetylcholine receptors
EA200600787A1 (ru) 2003-10-17 2006-08-25 Глэксо Груп Лимитед Антагонисты мускариновых ацетилхолиновых рецепторов
PE20050489A1 (es) 2003-11-04 2005-09-02 Glaxo Group Ltd Antagonistas de receptores de acetilcolina muscarinicos
JP4851937B2 (ja) 2003-11-21 2012-01-11 セラヴァンス， インコーポレーテッド β２アドレナリン作動性受容体作動薬活性およびムスカリン受容体拮抗薬活性を有する化合物
AR046783A1 (es) 2003-12-03 2005-12-21 Glaxo Group Ltd Compuesto de sal ciclica de amonio cuaternario composicion farmaceutica que lo comprende y su uso para preparar esta ultima
PE20050897A1 (es) 2003-12-03 2005-11-06 Glaxo Group Ltd Nuevos antagonistas del receptor muscarinico m3 de acetilcolina
TW200534855A (en) 2004-01-13 2005-11-01 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
US20090253908A1 (en) 2004-03-11 2009-10-08 Glaxo Group Limited Novel m3 muscarinic acetylchoine receptor antagonists
JP2007530451A (ja) 2004-03-11 2007-11-01 グラクソ　グループ　リミテッド 新規ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト
WO2005095407A1 (en) 2004-03-17 2005-10-13 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
JP2007529514A (ja) 2004-03-17 2007-10-25 グラクソ　グループ　リミテッド Ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト
JP2007529512A (ja) 2004-03-17 2007-10-25 グラクソ　グループ　リミテッド ムスカリン性アセチルコリン受容体アンタゴニスト
US20070185148A1 (en) 2004-03-17 2007-08-09 Glaxo Group Limited M3 muscarinic acetylchoine receptor antagonists
US20070238751A1 (en) 2004-04-07 2007-10-11 Laine Dramane I Muscarinic Acetylcholine Receptor Antagonists
PE20060259A1 (es) 2004-04-27 2006-03-25 Glaxo Group Ltd Compuestos de quinuclidina como antagonistas del receptor de acetilcolina muscarinico
JP2007537261A (ja) 2004-05-13 2007-12-20 グラクソ　グループ　リミテッド ムスカリン性アセチルコリン受容体アンタゴニスト
PE20060367A1 (es) 2004-05-28 2006-04-28 Glaxo Group Ltd Compuestos 8-azoniabiciclo[3.2.1]octanos como antagonistas del receptor de acetilcolina muscarinico
WO2006005057A2 (en) 2004-06-30 2006-01-12 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
EP1781104A4 (en) 2004-08-05 2008-05-21 Glaxo Group Ltd ANTAGONISTS OF THE ACETYLCHOLINE MUSCARINIC RECEPTOR
JP2008509158A (ja) 2004-08-06 2008-03-27 グラクソ グループ リミテッド ムスカリン性アセチルコリン受容体アンタゴニスト
JP2008518939A (ja) 2004-10-29 2008-06-05 グラクソ グループ リミテッド ムスカリン性アセチルコリン受容体アンタゴニスト
US7932247B2 (en) 2004-11-15 2011-04-26 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
EP1827439A4 (en) 2004-11-15 2009-11-18 Glaxo Group Ltd NEW M3 MUSCARIN ACETYLCHOLINE RECEPTOR ANTAGONISTS
PE20060826A1 (es) 2004-12-06 2006-10-08 Smithkline Beecham Corp Derivado oleofinico de 8-azoniabiciclo[3.2.1]octano y combinacion farmaceutica que lo comprende
PE20061162A1 (es) 2004-12-06 2006-10-14 Smithkline Beecham Corp Compuestos derivados olefinicos de 8-azoniabiciclo[3.2.1]octanos
WO2006065788A2 (en) 2004-12-13 2006-06-22 Glaxo Group Limited Novel muscarinic acetylcholine receptor antagonists
WO2006065755A2 (en) 2004-12-13 2006-06-22 Glaxo Group Limited Quaternary ammonium salts of fused hetearomatic amines as novel muscarinic acetylcholine receptor antagonists
WO2007018514A1 (en) 2005-07-28 2007-02-15 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
WO2007018508A1 (en) 2005-07-28 2007-02-15 Glaxo Group Limited Novel m3 muscarinic acetycholine receptor antagonists
EP1937267A4 (en) 2005-08-02 2009-08-26 Glaxo Group Ltd M3-MUSCARIN ACETYLCHOLIN RECEPTOR ANTAGONISTS
WO2007016650A2 (en) 2005-08-02 2007-02-08 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
JP2009504768A (ja) 2005-08-18 2009-02-05 グラクソ グループ リミテッド ムスカリン性アセチルコリン受容体アンタゴニスト
GB0921075D0 (en) * 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents

Also Published As

Publication number Publication date
CY2014043I2 (el) 2015-12-09
NO20065417L (no) 2006-12-29
SI1740177T1 (sl) 2012-12-31
FR14C0075I2 (fr) 2015-05-22
FR14C0075I1 (fr) 2014-11-21
EA200601991A1 (ru) 2007-02-27
NL300694I2 (en:Method) 2015-12-29
SG186597A1 (en) 2013-01-30
US9144571B2 (en) 2015-09-29
HUS1400053I1 (hu) 2017-07-28
DK1740177T3 (da) 2012-10-29
KR20110010841A (ko) 2011-02-07
US20070249664A1 (en) 2007-10-25
US20140080863A1 (en) 2014-03-20
EA021994B1 (ru) 2015-10-30
LT2570128T (lt) 2016-10-10
AP2213A (en) 2011-03-01
US20160002220A1 (en) 2016-01-07
NO2017018I1 (no) 2017-05-04
LU92565I9 (en:Method) 2019-01-17
EP2570128B1 (en) 2016-08-10
KR101152032B1 (ko) 2012-06-11
ES2392848T3 (es) 2012-12-14
DK2570128T3 (en) 2016-11-07
EP1740177B1 (en) 2012-08-08
US20120157491A1 (en) 2012-06-21
US20150238470A1 (en) 2015-08-27
EP1740177A4 (en) 2010-05-05
ECSP066940A (es) 2006-12-20
CN102040602A (zh) 2011-05-04
PL1740177T3 (pl) 2012-12-31
HRP20161385T1 (hr) 2016-12-02
SI2570128T1 (sl) 2016-11-30
BRPI0510170B1 (pt) 2018-12-18
CA2755954C (en) 2014-02-18
US20070185155A1 (en) 2007-08-09
PT2570128T (pt) 2016-10-07
LU92565I2 (fr) 2014-12-02
US20130030015A1 (en) 2013-01-31
BRPI0510170B8 (pt) 2021-05-25
NO338959B1 (no) 2016-11-07
IL178152A0 (en) 2006-12-31
MY144753A (en) 2011-10-31
CA2564742A1 (en) 2005-11-10
MXPA06012405A (es) 2007-01-17
EA201100019A1 (ru) 2011-12-30
PL2570128T3 (pl) 2017-09-29
JP5398871B2 (ja) 2014-01-29
CA2755954A1 (en) 2005-11-10
NO2017017I1 (no) 2017-05-04
KR20070015412A (ko) 2007-02-02
WO2005104745A3 (en) 2006-08-03
NL300694I1 (en:Method) 2015-12-29
PE20060259A1 (es) 2006-03-25
US7488827B2 (en) 2009-02-10
WO2005104745A2 (en) 2005-11-10
ES2600405T3 (es) 2017-02-08
CY2014043I1 (el) 2015-12-09
HUE031304T2 (hu) 2017-07-28
US8853404B2 (en) 2014-10-07
ES2392848T4 (es) 2014-10-01
AR050902A1 (es) 2006-12-06
US20140371264A1 (en) 2014-12-18
EP2570128A1 (en) 2013-03-20
ZA200608565B (en) 2019-12-18
TW200605887A (en) 2006-02-16
KR101037026B1 (ko) 2011-05-25
EP1740177A2 (en) 2007-01-10
US9045469B2 (en) 2015-06-02
CY1113196T1 (el) 2015-12-09
EA015033B1 (ru) 2011-04-29
IL178152A (en) 2011-05-31
HRP20120832T1 (hr) 2012-11-30
JP5014121B2 (ja) 2012-08-29
NO2017018I2 (no) 2018-05-14
UY28871A1 (es) 2005-11-30
AU2005237576B2 (en) 2012-01-12
EP3111936A1 (en) 2017-01-04
CN1976701A (zh) 2007-06-06
JP2012162559A (ja) 2012-08-30
BRPI0510170A (pt) 2007-10-02
NZ549997A (en) 2010-10-29
BE2014C063I2 (en:Method) 2024-08-08
TWI363759B (en) 2012-05-11
HK1102423A1 (en) 2007-11-23
US8183257B2 (en) 2012-05-22
US8309572B2 (en) 2012-11-13
CY1118082T1 (el) 2017-06-28
US20090124653A1 (en) 2009-05-14
UA95768C2 (ru) 2011-09-12
JP2007534769A (ja) 2007-11-29
US7498440B2 (en) 2009-03-03
PT1740177E (pt) 2012-11-02
CA2564742C (en) 2012-01-10
AP2006003746A0 (en) 2006-10-31
AU2005237576A1 (en) 2005-11-10
US8575347B2 (en) 2013-11-05

Similar Documents

Publication Publication Date Title
MA28631B1 (fr) Antagonistes des recepteurs muscariniques de l'acetylcholine
MA28363A1 (fr) Antagonistes des recepteurs muscariniques de l'acetylcholine
EP2049110A4 (en) BRAZED DIAZEPANOREXINE RECEPTOR ANTAGONISTS
IS8522A (is) Ný M3 múskarínasetýlkólínviðtakamótlyf
IS8515A (is) Ný M3 múskarínasetýlkólínviðtakamótlyf
IL188112A0 (en) Muscarinic acetylcholine receptor antagonists
DK1682142T3 (da) M3-muscarin-acetylcholin-receptor-antagonister
EP1725240A4 (en) ANTAGONISTS OF THE ACETYLCHOLINE MUSCARINIC RECEPTOR
ZA200602783B (en) Muscarinic acetylcholine receptor antagonists
EP1725238A4 (en) M 3 MUSCARINACETYLCHOLINE RECEPTOR ANTAGONISTS
EP1937068A4 (en) ANTAGONISTS OF ACETYLCHOLINE MUSCARINIC RECEPTORS
EP1648460A4 (en) ANTAGONISTS OF MUSCARIN ACETYLCHOLIN RECEPTOR
EP1725236A4 (en) NEW M3 MUSCARIN ACETYLCHOLINE RECEPTOR ANTAGONISTS
IL172911A0 (en) Muscarinic acetylcholine receptor antagonists
IL172912A0 (en) Muscarinic acetylcholine receptor antagonists
MA28602B1 (fr) Pyridin-4-yl-ethynyl-imidazoles et pyrazoles en tant qu'antagonistes des recepteurs mglur5
EP1747219A4 (en) Antagonists of muscarinic acetylcholine receptor
EP1824483A4 (en) ANTAGONISTS OF ACETYLCHOLINE MUSCARINIC RECEPTORS
EP1749012A4 (en) ANTAGONISTS OF MUSCARIN ACETYLCHOLIN RECEPTOR
EP2076285A4 (en) ANTIBODY ANTAGONISTS OF INTERLEUKIN 13 RECEPTOR 1
EP1898905A4 (en) HYDROISOINDOLIN-tachykinin receptor Antagonist
EP1765339A4 (en) ANTAGONISTS OF MUSCARIN ACETYLCHOLIN RECEPTOR
EP1781104A4 (en) ANTAGONISTS OF THE ACETYLCHOLINE MUSCARINIC RECEPTOR
EP1781103A4 (en) ANTAGONISTS OF THE ACETYLCHOLINE MUSCARINIC RECEPTOR
AP2008004537A0 (en) Muscarinic receptor antagonists